Prostate cancer markers

• US 6,673,545 B2
• Filed: 07/30/2001
• Issued: 01/06/2004
• Est. Priority Date: 07/28/2000
• Status: Expired due to Fees

• Current Assignee: Incyte Genomics, Inc. (Incyte Corporation)
• Original Assignee: Incyte Corporation
• Inventors: Turner, Christopher M., Faris, Mary
• Primary Examiner(s): Marschel, Ardin H.
• Assistant Examiner(s): Smith, Carolyn L
• Application Number:
  US09/919,172
• Publication Number:
  US 20020119463A1
• Time in Patent Office: 890 Days
• Field of Search: 536/23.1, 435/6, 435/287.2, 435/7.1
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.

Claims

1. A combination comprising a plurality of cDNAs that are differentially expressed in prostate cancer, wherein the plurality of cDNAs consist of SEQ ID NOs:

1-3, 5, 6, 8, 10-15, 17-19, 21, 23-28, 30, 32, 34-36, 38, 40, 42-45, 47-50, 52, 53, 55, 56, 58-65, 67, 68, 70-73, 75, 76, 78-86, 88-90, 92-97, 99-101 or a plurality of cDNAs consisting of the complements thereof.

2. The combination of claim 1, wherein each of the cDNAs is differentially regulated between non-metastatic and metastatic prostate cancer, consisting of SEQ ID NOs:

1-3, 5, 6, 8, 10-15, 17-19, 21, 23-28, 30, 32, 34-36, 38, 40, 42-45, 47-50, 52, 53, 55, 56, 58-65, 67, 68, 70-73, 75.

3. The combination of claim 1, wherein each of the cDNAs is differentially regulated between prostate cancer and normal prostate, consisting of SEQ ID NOs:

76, 78-86, 88-90, 92-97, 99-101.

4. The combination of claim 1, wherein the cDNAs are immobilized on a substrate.

5. A high throughput method for detecting differential expression of one or more cDNAs in a sample containing nucleic acids, the method comprising:

(a) hybridizing the substrate of claim 4 with nucleic acids of the sample, thereby forming one or more hybridization complexes;

(b) detecting the hybridization complexes; and

(c) comparing the hybridization complexes with those of a standard, wherein differences between the standard and sample hybridization complexes indicate differential expression of cDNAs in the sample.

6. The method of claim 5, wherein the nucleic acids of the sample are amplified prior to hybridization.

7. The method of claim 5, wherein the sample is from a subject with prostate cancer and comparison with a standard defines an early, mid, or late stage of that disease.

8. A high throughput method of screening a plurality of molecules or compounds to identify a ligand which specifically binds a cDNA, the method comprising:

(a) combining the composition of claim 1 with the plurality of molecules or compounds under conditions to allow specific binding; and

(b) detecting specific binding between each cDNA and at least one molecule or compound, thereby identifying a ligand that specifically binds to each cDNA.

9. The method of claim 8 wherein the plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and regulatory proteins.